Industry Calls For Changes To Maximize Benefits Of Off-Patent Oncology Drugs
Medicines For Europe Calls for ‘Highest Quality Patent System In Europe’
Medicines for Europe has made a series of recommendations to improve the contribution of generics, biosimilars and value-added medicines to the European Commission’s “Beating Cancer Plan.” The association has offered a checklist of key policies to “ensure equity and quality of cancer care is achieved.”
You may also be interested in...
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.
ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.